ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (OTCBB:BTIM) announced that it will host a conference call on which its Chief Executive Officer, Dr. Michael D. West, will discuss the opportunities presented by the recent additions to the company’s stem cell technology portfolio. BioTime, and its wholly owned subsidiary, Embryome Sciences, Inc., have acquired licenses for a portfolio of stem cell technology patents and patent applications. These licenses include technology that allows the rapid isolation of novel highly purified embryonic progenitor cells, technology for producing induced pluripotent stem cells (“iPS”), embryonic stem cell differentiation technology, and other technology for the manufacture and commercialization of human embryonic stem cell-derived cell types and related products.
